431
Views
25
CrossRef citations to date
0
Altmetric
Original Article: Clinical

18F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study

, , , , , , , , , , , , , , , , , , , , & show all
Pages 2005-2012 | Received 13 Jun 2014, Accepted 04 Oct 2014, Published online: 20 Nov 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Jihyun Kim, Yoo Sung Song, Jong Seok Lee, Won Woo Lee & Sang Eun Kim. (2018) Risk stratification of diffuse large B-cell lymphoma with interim PET-CT based on different cutoff Deauville scores. Leukemia & Lymphoma 59:2, pages 340-347.
Read now

Articles from other publishers (24)

Nicklas B. Nielsen, Oke Gerke, Anne L. Nielsen, Karen Juul‐Jensen, Thomas S. Larsen, Michael B. Møller & Malene G. Hildebrandt. (2023) A retrospective head‐to‐head comparison of the Lugano classification and PERCIST for FDG‐PET/CT response assessment in diffuse large B‐cell lymphoma. Clinical Physiology and Functional Imaging 44:1, pages 70-78.
Crossref
Tarec Christoffer El‐Galaly, Diego Villa, Chan Yoon Cheah & Lars C. Gormsen. (2022) Pre‐treatment total metabolic tumour volumes in lymphoma: Does quantity matter?. British Journal of Haematology 197:2, pages 139-155.
Crossref
Luca Ceriani & Emanuele Zucca. 2022. Nuclear Medicine and Molecular Imaging. Nuclear Medicine and Molecular Imaging 370 386 .
David Mankoff & Lawrence H. Schwartz. 2021. Quantitative Imaging in Medicine. Quantitative Imaging in Medicine 11-1 11-16 .
Sally F. Barrington, Jakoba J. Eertink, Henrika C. W. de Vet, N. George Mikhaeel, Otto S. Hoekstra & Josee M. Zijlstra. (2021) Not Yet Time to Abandon the Deauville Criteria in Diffuse Large B-Cell Lymphoma. Journal of Nuclear Medicine 62:11, pages 1655.2-1656.
Crossref
Meral Uluköylü Mengüç, Özgür Mehtap, Gözde Dağlıöz Görür, Elif Birtaş Ateşoğlu, Ayfer Gedük, Serkan Ünal, Pınar Tarkun & Abdullah Hacıhanefioğlu. (2021) The Role of Interim PET/CT on Survival in Diffuse Large B Cell Lymphoma. Clinical Lymphoma Myeloma and Leukemia 21:11, pages e922-e927.
Crossref
Lars Kurch, Andreas Hüttmann, Thomas W. Georgi, Jan Rekowski, Osama Sabri, Christine Schmitz, Regine Kluge, Ulrich Dührsen & Dirk Hasenclever. (2021) Interim PET in Diffuse Large B-Cell Lymphoma. Journal of Nuclear Medicine 62:8, pages 1068-1074.
Crossref
J. J. Eertink, C. N. Burggraaff, M. W. HeymansU. Dührsen, A. Hüttmann, C. Schmitz, S. MüllerP. J. Lugtenburg, S. F. Barrington, N. G. Mikhaeel, R. Carr, S. CziborT. Györke, L. Ceriani, E. Zucca, M. Hutchings, L. KostakogluA. LoftS. Fanti, S. E. Wiegers, S. Pieplenbosch, R. Boellaard, O. S. Hoekstra, J. M. Zijlstra & H. C. W. de Vet. (2021) Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients. Blood Advances 5:9, pages 2375-2384.
Crossref
N. George Mikhaeel, David Cunningham, Nicholas Counsell, Andrew McMillan, John A. Radford, Kirit M. Ardeshna, Anthony Lawrie, Paul Smith, Laura Clifton‐Hadley, Michael J. O'Doherty & Sally F. Barrington. (2020) FDG‐PET/CT after two cycles of R‐CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome – final result of a UK National Cancer Research Institute prospective study. British Journal of Haematology 192:3, pages 504-513.
Crossref
Sally F Barrington & Judith Trotman. (2021) The role of PET in the first-line treatment of the most common subtypes of non-Hodgkin lymphoma. The Lancet Haematology 8:1, pages e80-e93.
Crossref
David A. Mankoff. 2021. Molecular Imaging. Molecular Imaging 1503 1516 .
Amy J Weisman, Minnie W Kieler, Scott Perlman, Martin Hutchings, Robert Jeraj, Lale Kostakoglu & Tyler J Bradshaw. (2020) Comparison of 11 automated PET segmentation methods in lymphoma. Physics in Medicine & Biology 65:23, pages 235019.
Crossref
Hye Park, Eun Han, Joo O, Byung-Ock Choi, Gyeongsin Park, Seung-Eun Jung, Seung-Ah Yahng, Ki-Seong Eom & Seok-Goo Cho. (2020) Early Interim Chemotherapy Response Evaluation by F-18 FDG PET/CT in Diffuse Large B Cell Lymphoma. Diagnostics 10:12, pages 1002.
Crossref
Amy J. Weisman, Minnie W. Kieler, Scott B. Perlman, Martin Hutchings, Robert Jeraj, Lale Kostakoglu & Tyler J. Bradshaw. (2020) Convolutional Neural Networks for Automated PET/CT Detection of Diseased Lymph Node Burden in Patients with Lymphoma. Radiology: Artificial Intelligence 2:5, pages e200016.
Crossref
A. Panteleichuk, M. Kadzhaya, V. Biloschytsky, A. Shmeleva, T. Petriv, O. Gnatyuk, G. Dovbeshko, R. Kozakevych & V. Tyortyh. (2020) Composite chitosan/polyethylene oxide film for duraplasty in traumatic brain injury model in rats. Cell and Organ Transplantology 8:1.
Crossref
Mathieu N. Toledano, Pierre Vera, Hervé Tilly, Fabrice Jardin & Stéphanie Becker. (2019) Comparison of therapeutic evaluation criteria in FDG-PET/CT in patients with diffuse large-cell B-cell lymphoma: Prognostic impact of tumor/liver ratio. PLOS ONE 14:2, pages e0211649.
Crossref
Ling Yuan, Michael C. Kreissl, Liping Su, Zhifang Wu, Marcus Hacker, Jianzhong Liu, Xi Zhang, Yunfeng Bo, Hongyu Zhang, Xiang Li & Sijin Li. (2018) Prognostic analysis of interim 18F-FDG PET/CT in patients with diffuse large B cell lymphoma after one cycle versus two cycles of chemotherapy. European Journal of Nuclear Medicine and Molecular Imaging 46:2, pages 478-488.
Crossref
Coreline N. Burggraaff, Antoinette de Jong, Otto S. Hoekstra, Nikie J. Hoetjes, Rutger A. J. Nievelstein, Elise P. Jansma, Martijn W. Heymans, Henrica C. W. de Vet & Josée M. Zijlstra. (2018) Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysis. European Journal of Nuclear Medicine and Molecular Imaging 46:1, pages 65-79.
Crossref
Lucia Baratto, Guido A. Davidzon, Mateen Moghbel, Negin Hatami, Andrei Iagaru & Erik S. Mittra. (2018) Comparison Between Different PET and CT-Based Imaging Interpretation Criteria at Interim Imaging in Patients With Diffuse Large B-Cell Lymphoma. Clinical Nuclear Medicine 43:1, pages 1-8.
Crossref
Steven Le GouillRené-Olivier Casasnovas. (2017) Interim PET-driven strategy in de novo diffuse large B-cell lymphoma: do we trust the driver?. Blood 129:23, pages 3059-3070.
Crossref
Gunjan L. Shah & Craig H. Moskowitz. (2016) Role of Positron Emission Tomography in Diffuse Large B-cell Lymphoma. Hematology/Oncology Clinics of North America 30:6, pages 1215-1228.
Crossref
Sally F. Barrington & N. George Mikhaeel. (2016) PET Scans for Staging and Restaging in Diffuse Large B-Cell and Follicular Lymphomas. Current Hematologic Malignancy Reports 11:3, pages 185-195.
Crossref
Tarec Christoffer El‐Galaly, Martin Bjerregård Pedersen, Martin Hutchings, Karen Juul Mylam, Jakob Madsen, Anne Ortved Gang, Martin Bøgsted, Peter de Nully Brown, Annika Loft, Anne Lerberg Nielsen, Helle Westergreen Hendel, Victor Iyer & Lars Christian Gormsen. (2015) Utility of interim and end‐of‐treatment PET/CT in peripheral T‐cell lymphomas: A review of 124 patients. American Journal of Hematology 90:11, pages 975-980.
Crossref
Lode J. Swinnen, Hailun Li, Andrew Quon, Randy Gascoyne, Fangxin Hong, Erik A. Ranheim, Thomas M. Habermann, Brad S. Kahl, Sandra J. Horning & Ranjana H. Advani. (2015) Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404). British Journal of Haematology 170:1, pages 56-65.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.